Document is current
Any future updates will be listed below
-
Authors
Stebbing, Justin https://orcid.org/0000-0002-1117-6947
Krishnan, Venkatesh https://orcid.org/0000-0002-3295-6598
de Bono, Stephanie
Ottaviani, Silvia
Casalini, Giacomo
Richardson, Peter J
Monteil, Vanessa
Lauschke, Volker M
Mirazimi, Ali
Youhanna, Sonia
Tan, Yee‐Joo
Baldanti, Fausto
Sarasini, Antonella
Terres, Jorge A Ross
Nickoloff, Brian J
Higgs, Richard E
Rocha, Guilherme
Byers, Nicole L
Schlichting, Douglas E
Nirula, Ajay
Cardoso, Anabela
Corbellino, Mario
,
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
Sacco Baricitininb Study Group
- License Information
-
More Information
Article History
Received: 16 May 2020
Revised: 22 May 2020
Accepted: 28 May 2020
First Online: 24 June 2020
Conflict of interest
: JS is editor‐in‐chief of Oncogene. JS has sat on a number of scientific advisory boards, including BenevolentAI, and consults with Lansdowne partners and Vitruvian, and since these findings in patients, consults with Eli Lilly and Company; he sits on the Board of Directors for BB Biotech Healthcare Trust. VML is the founder, CEO, and shareholder of HepaPredict AB. In addition, VML discloses consultancy work for EnginZyme AB. VM, AM, SO, MC, and GC report no conflicts of interest. PJR is an employee of BenevolentAI. VK, SdB, JART, BJN, REH, GR, NLB, DES, AN, and AC are employees and shareholders of Eli Lilly and Company.
